RGEN Stock Analysis: Buy, Sell, or Hold?
RGEN - Repligen Corp
$181.13
0.84 (0.47%)
▲
5d:
+8.57%
30d:
+31.64%
90d:
+59.77%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RGEN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$128.48
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$79.78
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $181.13, which is considered extended relative to its 30-day fair value range of $139.76 to $167.60. From a valuation perspective, the stock is trading at a premium (Forward PE: 68.3) compared to its historical average (58.6). At these levels, the market is pricing in 5.2% annual earnings growth.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $160.99, while resistance sits at $188.73.
Market Sentiment: RGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $160.99, while resistance sits at $188.73.
Market Sentiment: RGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$139.76 -
$167.60
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
22.4%
All Signals
- BEARISH: Price extended above range (+8.1% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($185.70)
- BULLISH: Expecting earnings turnaround to 5.2% growth with 11.9% revenue growth
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$139.76 -
$167.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$160.99
Resistance Level
$188.73
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
68.31
Wall Street Target
$185.70
(+3.0%)
Revenue Growth (YoY)
11.9%
Earnings Growth (YoY)
-65.9%
Profit Margin
5.3%
Valuation Premium vs History
+5.2% premium
PE vs Historical
68.3 vs 58.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.2%
(market-implied from PE analysis)
1-Year Target
$189.67
(+5%)
2-Year Target
$199.53
(+11%)
3-Year Target
$209.90
(+16%)
3-Yr Target (if PE normalizes)
(PE: 68→59)
PE COMPRESSION
$180.05
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 68.3, Growth: 27.9%)
$376.78
(+109%)
Base:
(SPY PE: 20.1, Growth: 27.9%)
$110.69
(-39%)
Bear:
(PE: 17.1, Growth: 27.9%)
$94.09
(-48%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (81x PE), but valuation improves significantly next year (68x PE) as earnings recover.
Forward PE: 81.30 | Forward EPS (Implied): $2.23
Bull Case
$218.71
(+21%)
Analyst growth 15.0%, PE expands to 85.4
Base Case
$181.13
(0%)
Market implied 0.0%, PE stable at 81.3
Bear Case
$138.56
(-24%)
Severe decline -15.0%, PE contracts to 73.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 12:04 PM ET
Data refreshes hourly during market hours. Next update: 1:04 PM
Data refreshes hourly during market hours. Next update: 1:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 46 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$85 | 37 SELL |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 66 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$246 | 41 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$82 | 44 HOLD |
